MedTrace Logo

Effect of 0.75% Piroctone Olamine Shampoo on the Hair and Scalp Microbiota of Hijab-Wearing Women With Seborrheic Dermatitis in Indonesia

NCT07802808 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-09-03

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether piroctone olamine shampoo works as well as ketoconazole shampoo to improve seborrheic dermatitis (dandruff) in hijab-wearing women in Indonesia. It will also assess the safety of piroctone olamine shampoo. The main questions it aims to answer are:

1. Does piroctone olamine shampoo improve the signs and symptoms of seborrheic dermatitis?
2. Does piroctone olamine shampoo cause any scalp or hair-related side effects?

Researchers will compare piroctone olamine shampoo with ketoconazole shampoo to assess their effects on seborrheic dermatitis.

Participants will:

1. Attend screening and study visits for scalp and hair examinations.
2. Use either piroctone olamine shampoo or ketoconazole shampoo as instructed during the study.
3. Provide hair and scalp samples for microbiota testing and superoxide dismutase testing.
4. Have scalp hydration, water loss, and sebum levels measured.
5. Report any discomfort, scalp irritation, or other side effects during the study.

Conditions

Interventions

DRUG

Piroctone Olamine 0.75% Shampoo

Shampoo containing Piroctone Olamine 0.75%

DRUG

Ketoconazole Shampoo, 2%

Ketoconazole shampoo

Sponsors & Collaborators

  • PT Paragon Technology and Innovation

    collaborator UNKNOWN

  • Indonesia University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-12
Primary Completion
2026-02-02
Completion
2026-02-02

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07802808 on ClinicalTrials.gov